CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 84 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q4 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $85,000 | +57.4% | 43,200 | 0.0% | 0.00% | – |
| Q4 2020 | $54,000 | -66.0% | 43,200 | -51.1% | 0.00% | – |
| Q3 2020 | $159,000 | -85.6% | 88,300 | -33.1% | 0.00% | -100.0% |
| Q2 2020 | $1,107,000 | +60.7% | 132,000 | +0.4% | 0.00% | – |
| Q1 2020 | $689,000 | +43.8% | 131,500 | +49.8% | 0.00% | – |
| Q4 2019 | $479,000 | +11.9% | 87,800 | 0.0% | 0.00% | – |
| Q3 2019 | $428,000 | -29.6% | 87,800 | 0.0% | 0.00% | – |
| Q2 2019 | $608,000 | -0.3% | 87,800 | 0.0% | 0.00% | – |
| Q1 2019 | $610,000 | +15.5% | 87,800 | -2.9% | 0.00% | – |
| Q4 2018 | $528,000 | +26.3% | 90,400 | +63.2% | 0.00% | – |
| Q3 2018 | $418,000 | +141.6% | 55,400 | +61.5% | 0.00% | – |
| Q2 2018 | $173,000 | +1.8% | 34,300 | +23.4% | 0.00% | – |
| Q1 2018 | $170,000 | +57.4% | 27,800 | +82.9% | 0.00% | – |
| Q4 2017 | $108,000 | +36.7% | 15,200 | +38.2% | 0.00% | – |
| Q3 2017 | $79,000 | +14.5% | 11,000 | 0.0% | 0.00% | – |
| Q2 2017 | $69,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $3,107,000 | 1.71% |
| ETF MANAGERS GROUP, LLC | 14,138,998 | $8,534,000 | 0.17% |
| Ikarian Capital, LLC | 948,526 | $584,000 | 0.09% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 318,668 | $196,000 | 0.03% |
| Platform Technology Partners | 45,000 | $28,000 | 0.01% |
| XTX Topco Ltd | 34,476 | $21,000 | 0.01% |
| PINNACLE ASSOCIATES LTD | 947,083 | $583,000 | 0.01% |
| Penserra Capital Management LLC | 537,236 | $330,000 | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 4,070,006 | $2,506,000 | 0.01% |
| Tekla Capital Management LLC | 154,310 | $95,000 | 0.00% |